User profiles for Sarayut Lucien Geater
 | Sarayut L. GeaterResearcher | Lecturer of Medicine, Prince of Songkla University Verified email at psu.ac.th Cited by 19546 |
[PDF][PDF] Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Purpose The LUX-Lung 3 study investigated the efficacy of chemotherapy compared with
afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling …
afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling …
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2 …
JCH Yang, LV Sequist, SL Geater, CM Tsai… - The lancet …, 2015 - thelancet.com
Background Most patients with non-small-cell lung cancer tumours that have EGFR mutations
have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21, or both (ie…
have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21, or both (ie…
Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non–small-cell lung cancer: the phase III POSEIDON …
…, A Luft, J Alatorre-Alexander, SL Geater… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE The open-label, phase III POSEIDON study evaluated tremelimumab plus
durvalumab and chemotherapy (T + D + CT) and durvalumab plus chemotherapy (D + CT) versus …
durvalumab and chemotherapy (T + D + CT) and durvalumab plus chemotherapy (D + CT) versus …
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
…, K Kubiak, A Santoro, MN Uy, SL Geater… - The Lancet …, 2018 - thelancet.com
Background Immune checkpoint inhibitors are a new standard of care for patients with
advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic …
advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic …
Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non–small cell lung cancer: the MYSTIC phase 3 randomized …
…, R Natale, J Schneider, FA Shepherd, SL Geater… - JAMA …, 2020 - jamanetwork.com
Importance Checkpoint inhibitors targeting programmed cell death 1 or its ligand (PD-L1) as
monotherapies or in combination with anti–cytotoxic T-lymphocyte–associated antigen 4 …
monotherapies or in combination with anti–cytotoxic T-lymphocyte–associated antigen 4 …
LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma …
…, N Yamamoto, KJ O'Byrne, V Hirsh, T Mok, SL Geater… - 2012 - ascopubs.org
LBA7500 Background: Afatinib (A) is a selective, orally bioavailable, irreversible ErbB family
blocker of EGFR (ErbB1), HER2 (ErbB2), and ErbB4. This global study investigated the …
blocker of EGFR (ErbB1), HER2 (ErbB2), and ErbB4. This global study investigated the …
[HTML][HTML] Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX …
Background Afatinib 40 mg/day is approved for first-line treatment of EGFR mutation-positive
non-small-cell lung cancer (NSCLC). In the case of drug-related grade ≥3 or selected …
non-small-cell lung cancer (NSCLC). In the case of drug-related grade ≥3 or selected …
LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR …
…, D Massey, Y Shi, J Chen, V Zazulina, SL Geater - 2013 - ascopubs.org
8016 Background: A is an oral, irreversible, ErbB Family Blocker, blocking signaling from
EGFR (ErbB1), HER2 (ErbB2) and ErbB4. A was superior to first-line pemetrexed/cisplatin in a …
EGFR (ErbB1), HER2 (ErbB2) and ErbB4. A was superior to first-line pemetrexed/cisplatin in a …
Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor …
…, T Mok, N Yamamoto, KJ O'Byrne, V Hirsh, SL Geater… - 2014 - ascopubs.org
8004^ Background: Afatinib (A) is an oral, irreversible ErbB family blocker of EGFR, HER2,
ErbB3 and ErbB4 signalling. LL3 compared A with cisplatin/pemetrexed in 345 pts recruited …
ErbB3 and ErbB4 signalling. LL3 compared A with cisplatin/pemetrexed in 345 pts recruited …
CNS efficacy of osimertinib with or without chemotherapy in epidermal growth factor receptor–mutated advanced non–small-cell lung cancer
…, B Chewaskulyong, S Lucien Geater… - Journal of Clinical …, 2024 - ascopubs.org
PURPOSE We report CNS efficacy of first-line osimertinib plus chemotherapy versus
osimertinib monotherapy in patients with epidermal growth factor receptor (EGFR)–mutated …
osimertinib monotherapy in patients with epidermal growth factor receptor (EGFR)–mutated …